Eads & Heald Wealth Management Has $2.58 Million Holdings in Becton Dickinson and Co (BDX)

Eads & Heald Wealth Management lessened its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 3.0% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,901 shares of the medical instruments supplier’s stock after selling 308 shares during the period. Becton Dickinson and accounts for approximately 1.5% of Eads & Heald Wealth Management’s investment portfolio, making the stock its 7th biggest holding. Eads & Heald Wealth Management’s holdings in Becton Dickinson and were worth $2,584,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of BDX. Acropolis Investment Management LLC acquired a new stake in shares of Becton Dickinson and during the 3rd quarter worth about $101,000. Almanack Investment Partners LLC. acquired a new stake in shares of Becton Dickinson and during the 2nd quarter worth about $105,000. Truvestments Capital LLC purchased a new position in Becton Dickinson and during the 3rd quarter worth approximately $105,000. Bartlett & Co. LLC grew its stake in Becton Dickinson and by 2,900.0% during the 2nd quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock worth $108,000 after buying an additional 435 shares during the last quarter. Finally, Bridgeworth LLC purchased a new position in Becton Dickinson and during the 2nd quarter worth approximately $131,000. 92.57% of the stock is currently owned by institutional investors and hedge funds.

BDX has been the topic of a number of research reports. Morgan Stanley raised their price target on Becton Dickinson and from $250.00 to $280.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 4th. KeyCorp restated a “buy” rating and set a $264.00 price target on shares of Becton Dickinson and in a research note on Friday, August 3rd. Citigroup raised their price target on Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a research note on Wednesday, August 8th. Barclays initiated coverage on Becton Dickinson and in a research note on Monday, October 15th. They set an “equal weight” rating and a $278.00 price target on the stock. Finally, Royal Bank of Canada restated a “hold” rating and set a $248.00 price target on shares of Becton Dickinson and in a research note on Friday, August 3rd. Five analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $255.40.

Shares of BDX stock opened at $230.50 on Thursday. Becton Dickinson and Co has a twelve month low of $203.99 and a twelve month high of $265.87. The company has a market capitalization of $61.70 billion, a price-to-earnings ratio of 24.31, a P/E/G ratio of 1.37 and a beta of 1.11. The company has a current ratio of 1.23, a quick ratio of 0.81 and a debt-to-equity ratio of 0.95.

Becton Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, August 2nd. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating the consensus estimate of $2.86 by $0.05. Becton Dickinson and had a return on equity of 14.16% and a net margin of 4.73%. The company had revenue of $4.28 billion for the quarter, compared to the consensus estimate of $4.25 billion. During the same period last year, the business posted $2.46 EPS. The company’s revenue was up 41.0% on a year-over-year basis. On average, equities analysts expect that Becton Dickinson and Co will post 11.01 EPS for the current year.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Featured Story: How is inflation measured?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply